Clinical Trial ProgressRenovoRx is on track to complete enrollment in the 114-patient Phase 3 TIGeR-PaC study, which is crucial for advancing its treatment for pancreatic cancer.
Interim Analysis ResultsPositive data from the first interim analysis demonstrated an overall survival of approximately 21.5 months, compared to 15.5 months in the control arm, with a favorable safety profile.
Market PotentialRenovoRx has a significant market potential with its focus on Locally Advanced Pancreatic Cancer, one of the deadliest cancers with very poor prognosis and outcomes.